EPH - International Journal of Medical and Health Science

AI-DRIVEN PERSONALIZED MEDICINE: ASSESSING THE IMPACT OF FEDERAL POLICIESON ADVANCING PATIENT-CENTRIC CARE

Sarika Mulukuntla[1*], Saigurudatta Pamulaparthyvenkata[2]

[1*]Health IT Specialist, Dallas.

*Corresponding author: Saigurudatta Pamulaparthyvenkata

Abstract:
AI-driven personalized medicine represents a transformative approach in healthcare, promising to tailor treatment and preventive care to individual patient profiles. This paradigm shift, powered by advancements in artificial intelligence (AI), genomics, and data analytics, has the potential to dramatically improve patient outcomes and healthcare efficiency. However, the realization of its full potential is intricately linked to the regulatory and policy landscape shaped by federal entities. This article assesses the impact of federal policies on advancing AI-driven personalized medicine and fostering patient-centric care. Through a comprehensive review and analysis, it explores how current regulations support or hinder innovation in personalized healthcare, highlights the challenges and opportunities presented by the integration of AI technologies in medical practices, and proposes strategies to enhance policy frameworks to better accommodate the rapid pace of technological advancements. The findings underscore the critical role of federal policies in enabling the effective integration of AI into healthcare, advocating for a collaborative approach among policymakers, healthcare providers, and AI developers to create a conducive environment for the growth of AI-driven personalized medicine.

1.Introduction:AI-Driven Personalized Medicine and the Influence of Federal Policies on Advancing Patient-Centric Care

In the evolving landscape of healthcare, the emergence of AI-driven personalized medicine marks a pivotal transition from a one-size-fits-all approach to a more nuanced, individualized form of care. This paradigm shift not only promises to enhance the efficacy of treatments but also aligns with the burgeoning emphasis on patient-centric care. The essence of AI-driven personalized medicine lies in leveraging artificial intelligence (AI) to analyze vast amounts of health data, including genetic information, to tailor medical interventions to the unique needs of each patient. This innovative approach has the potential to revolutionize the way we diagnose, treat, and prevent diseases, making healthcare more predictive, preventative, and precise.

However, the path to fully integrating AI-driven personalized medicine into mainstream healthcare is complex and fraught with challenges. Among these, the role of federal policies is paramount. Government regulations, funding, and guidelines play a crucial role in shaping the development, validation, and implementation of AI-driven interventions. These policies can either accelerate the adoption of personalized medicine by providing the necessary support and framework or hinder its progress through restrictive regulations and insufficient funding.

The significance of patient-centric care in the context of AI-driven personalized medicine cannot be overstated. At its core, patient-centric care is about prioritizing the preferences, needs, and values of patients in all healthcare decisions and processes. In the era of personalized medicine, this approach becomes even more critical, as the very premise of AI-driven interventions is to cater to the individual characteristics of each patient. By aligning federal policies with the principles of patient-centric care, we can ensure that the development of AI-driven personalized medicine truly benefits the patients it aims to serve.

1.1 The Promise of AI-Driven Personalized Medicine

AI-driven personalized medicine represents a beacon of hope in addressing some of the most pressing challenges in healthcare. By harnessing AI to analyze genetic, environmental, and lifestyle factors, personalized medicine can identify the most effective treatments for individual patients, reducing the trial and error associated with traditional approaches. This not only improves patient outcomes but also reduces healthcare costs by minimizing the use of ineffective treatments. Furthermore, AI-driven personalized medicine holds the potential to identify at-risk individuals before diseases manifest, enabling preventative interventions that can dramatically alter the course of health outcomes. The ability of AI to process and learn from vast datasets also accelerates medical research, leading to faster discovery of new treatments and understanding of complex diseases.

1.2 The Crucial Role of Federal Policies

Federal policies play a dual role in the advancement of AI-driven personalized medicine. On one hand, they provide the necessary infrastructure, funding, and regulatory environment that facilitate research, development, and implementation of personalized interventions. Initiatives such as the Precision Medicine Initiative in the United States have shown the positive impact of federal support in advancing personalized medicine.

On the other hand, federal policies must also address the ethical, privacy, and security concerns associated with the use of AI and the handling of sensitive genetic and health data. Regulations that ensure the responsible use of AI, protect patient privacy, and promote data security are essential to maintain public trust and support for personalized medicine.

1.3 Aligning Federal Policies with Patient-Centric Care

To maximize the benefits of AI-driven personalized medicine, federal policies must be closely aligned with the principles of patient-centric care. This entails developing policies that not only support the technological and scientific advancements in personalized medicine but also ensure that these advancements are accessible and beneficial to all patients. Key considerations include ensuring equitable access to personalized interventions, involving patients in decision-making processes related to their care, and addressing disparities in healthcare that may hinder the effectiveness of personalized treatments.

Moreover, patient education and engagement should be central to policy-making in this area. By empowering patients with knowledge about the potential benefits and limitations of AI-driven personalized medicine, we can foster a healthcare environment that truly centers around the needs and preferences of patients.

2. Overview of AI-Driven Personalized Medicine
2.1 Introduction to AI-Driven Personalized Medicine

In the realm of modern healthcare, AI-driven personalized medicine emerges as a transformative approach, signaling a shift from the conventional generalist methods of disease management towards more individualized treatment strategies. This innovative approach integrates artificial intelligence (AI) with genomics and data analysis, offering a promise to revolutionize patient care by making it more precise, predictive, and personalized.

Definition and Scope

AI-driven personalized medicine refers to the utilization of artificial intelligence technologies to analyze and interpret vast datasets, including genetic information, lifestyle factors, and environmental exposures, to tailor healthcare interventions to the individual characteristics of each patient. This methodology extends beyond traditional treatments to encompass prevention, diagnosis, and management strategies that are specifically designed to cater to the unique needs of individuals, thereby optimizing the efficacy of healthcare outcomes.

Components of AI-Driven Personalized Medicine

The foundation of AI-driven personalized medicine is built on several key components:

● **Genomic Data:** The analysis of patients' genetic profiles to identify specific markers that predict disease risk, treatment response, and drug efficacy.

● **Clinical Data:** Comprehensive patient records that include medical history, laboratory results, and imaging studies, providing a holistic view of the patient's health status.

● **Lifestyle and Environmental Data:** Information on patients' lifestyle choices (such as diet, physical activity, and smoking status) and environmental exposures that can influence health outcomes.

● **AI and Machine Learning Algorithms:** Advanced computational tools that process and learn from vast datasets, identifying patterns and insights that inform personalized treatment plans.

● **Integrated Healthcare Systems:** The collaboration between various healthcare providers and technologies to ensure that personalized treatment strategies are seamlessly implemented and monitored.

2.2 Current Technologies and Methodologies

The advancement of AI-driven personalized medicine is fueled by rapid innovations in technology and methodologies. These include:

● **Genomic Sequencing:** High-throughput sequencing technologies that decode genetic information quickly and cost-effectively, identifying genetic variations linked to diseases and treatment responses.

● **Bioinformatics:** The use of software and computational methods to analyze complex biological data, enabling the identification of disease-causing genes and pathways.

● **Machine Learning and Predictive Analytics:** Algorithms that analyze data from multiple sources to predict disease risk, treatment outcomes, and potential side effects, facilitating decision-making in clinical settings.

● **Wearable Health Devices:** Technology that monitors patients' health in real-time, providing valuable data on physiological parameters and lifestyle habits that influence health outcomes.

● **Electronic Health Records (EHRs):** Digital systems that store patients' medical histories, streamlining the integration of personalized medicine into clinical practice by providing accessible, comprehensive patient data.

2.3 Examples of AI-Driven Personalized Medicine in Practice

AI-driven personalized medicine is not a futuristic concept; it is being implemented in various ways across the healthcare spectrum today. Examples include:

● **Oncology:** AI algorithms analyze genomic data from tumor samples to identify mutations and predict the most effective cancer treatments for individual patients, enhancing treatment precision and outcomes.

● **Pharmacogenomics:** The study of how genes affect a person's response to drugs, allowing for the personalization of medication dosages and combinations to maximize efficacy and minimize adverse effects.

● **Predictive Risk Modeling:** AI tools assess genetic, clinical, and lifestyle data to predict individuals' risk of developing certain conditions, such as cardiovascular diseases, enabling early intervention and preventative measures.

● **Chronic Disease Management:** Personalized treatment plans for conditions like diabetes and hypertension, informed by continuous data collection from wearable devices, improving disease control and patient quality of life.

3. Federal Policies Impacting Personalized Medicine

The evolution of personalized medicine, particularly AI-driven approaches, has been significantly influenced by a range of federal policies, regulations, and initiatives. These governmental actions have aimed to create an enabling environment for scientific innovation, ensure patient safety, and address the ethical, legal, and social implications of personalized medicine. Let's delve into some of the key federal policies that have played pivotal roles in this domain.

3.1 Key Federal Initiatives and Regulations

● **The Precision Medicine Initiative (PMI):** Launched in 2015, the PMI represents a bold national effort to drive the research and implementation of personalized medicine. It focuses on tailoring medical treatment to the individual characteristics of each patient, incorporating factors like genetic makeup, environment, and lifestyle. The initiative underscores the commitment of federal agencies to advancing personalized medicine through research, data sharing, and the development of new tools.

● **The 21st Century Cures Act:** Enacted in 2016, this act aimed to accelerate medical product development and bring innovations faster to patients who need them. It includes provisions to streamline the drug and device approval processes and emphasizes the importance of incorporating patient perspectives into the development and regulatory review process. The act also supports the use of real-world evidence and advanced biomarker technologies, which are crucial for personalized medicine.

● **HIPAA Privacy Rule and GINA:** The Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule and the Genetic Information Nondiscrimination Act (GINA) provide frameworks for protecting sensitive patient data and genetic information. These regulations are essential for maintaining trust in the use of personal health information in research and clinical settings, a cornerstone for the advancement of personalized medicine.

● **FDA's Framework for Precision Medicine:** The Food and Drug Administration (FDA) has developed specific frameworks and guidelines for the approval and oversight of personalized therapeutic products, including those driven by AI and machine learning. These guidelines aim to ensure the safety and efficacy of personalized treatments while fostering innovation in the sector.

3.2 Impact on AI-Driven Personalized Care
The policies and initiatives mentioned have had a profound impact on the landscape of AI-driven personalized medicine. They have both supported and, in some instances, presented challenges to the advancement of personalized care.

Supportive Aspects
●**Encouragement of Innovation:** Federal initiatives like the PMI and the 21st Century Cures Act have significantly boosted research and development in personalized medicine by providing funding and streamlining regulatory pathways. This support has facilitated the rapid development and implementation of AI technologies in healthcare.
●**Data Privacy and Security:** Regulations such as HIPAA and GINA play crucial roles in ensuring the privacy and security of patient data, which is fundamental for the ethical development and application of AI in healthcare. By safeguarding sensitive information, these policies help maintain public trust in personalized medicine approaches.
●**Guidance for New Technologies:** The FDA's evolving framework for precision medicine provides clear guidance for the development and approval of AI-driven treatments, ensuring that new innovations meet safety and efficacy standards before reaching patients.

Challenges and Limitations
●**Regulatory Hurdles:** While regulations are necessary for ensuring patient safety and efficacy of treatments, they can sometimes slow down the innovation process. The regulatory landscape for AI-driven technologies is still evolving, and navigating these waters can be challenging for developers and researchers.
●**Data Sharing and Interoperability:** Federal policies have emphasized the importance of data sharing and interoperability, but practical challenges remain. Ensuring that different systems and databases can communicate effectively is essential for the advancement of personalized medicine, yet achieving this interoperability is still a work in progress.

3.3 The Role of Regulatory Bodies
Regulatory bodies like the FDA and the National Institutes of Health (NIH) are at the forefront of shaping the development and implementation of personalized medicine.
●**FDA's Role:** The FDA has undertaken significant efforts to adapt its regulatory framework to accommodate the rapid advancements in personalized medicine. This includes creating specialized approval pathways for personalized therapeutics and diagnostics, as well as issuing guidelines on the use of AI and digital health technologies. The FDA also collaborates with stakeholders to understand the challenges and opportunities presented by personalized medicine.
●**NIH's Contribution:** The NIH, particularly through the PMI and its flagship All of Us Research Program, plays a critical role in funding and facilitating research in personalized medicine. The All of Us Research Program aims to gather health data from one million or more people living in the United States to accelerate research and improve health, emphasizing the diversity and inclusivity necessary for effective personalized medicine.

4. Analysis of AI-Driven Personalized Medicine and Federal Policies
In the rapidly evolving domain of healthcare, the convergence of artificial intelligence (AI) and personalized medicine heralds a new frontier in patient care. This transformative synergy promises to tailor healthcare to the individual, optimizing treatment outcomes and revolutionizing the medical landscape. However, the path to fully realizing the potential of AI-driven personalized medicine is intricately tied to the fabric of federal policies and regulatory frameworks. These policies play a critical role in shaping the development, validation, and implementation of AI technologies in healthcare. This analysis explores the interplay between AI advancements in personalized medicine and federal policy frameworks, delves into the challenges and opportunities of harmonizing technological innovations with regulatory requirements, and highlights case studies where federal policies have tangibly influenced the development or deployment of AI-driven solutions.

4.1 The Synergy Between AI Advancements and Policy Frameworks
The intersection of AI and personalized medicine is fertile ground for innovation, offering new avenues for diagnosing, treating, and preventing diseases more effectively. Federal policies and regulations are pivotal in nurturing this growth, ensuring that AI-driven approaches are developed and implemented responsibly, ethically, and with patient safety at the forefront. Initiatives such as the Precision Medicine Initiative (PMI) and regulations like the 21st Century Cures Act have provided a robust foundation for this synergy, facilitating research, development, and the integration of AI technologies in clinical settings.
The relationship between AI advancements and federal policies is inherently dynamic. Policies are designed not only to promote innovation but also to adapt to the fast-paced evolution of technology. This adaptability is crucial for maintaining a balance between fostering technological advancements and protecting patient rights and safety.

4.2 Harmonizing Technological Advancements with Regulatory Requirements
The fusion of AI with personalized medicine presents a unique set of challenges and opportunities in aligning technological progress with regulatory landscapes. One of the primary challenges lies in the novel nature of AI applications in healthcare, which often outpaces existing regulatory frameworks. Regulatory bodies, like the FDA, face the daunting task of evaluating the safety and efficacy of AI-driven interventions, a process traditionally geared towards more conventional medical treatments and devices.

Moreover, the proprietary algorithms and data privacy concerns associated with AI technologies add layers of complexity to regulatory approvals. Ensuring transparency, accountability, and patient privacy requires innovative regulatory approaches and continuous dialogue between technology developers, policymakers, and the healthcare community.

On the flip side, this dynamic landscape offers opportunities for regulatory innovation. The FDA's Digital Health Innovation Action Plan and the development of a regulatory framework for AI and machine learning-based medical devices are prime examples of regulatory bodies evolving to keep pace with technological advancements. These efforts not only support the safe integration of AI into healthcare but also encourage the development of new AI-driven solutions by providing clearer pathways to market.

4.3 Case Studies: Federal Policies and AI-Driven Solutions
Several case studies illustrate the direct impact of federal policies on the development and deployment of AI-driven personalized medicine solutions:

Case Study 1: Oncology Precision Medicine
In the field of oncology, the FDA's accelerated approval of AI-driven diagnostic tools for cancer treatment highlights the positive impact of federal policies. One such tool uses AI to analyze genetic data from tumor samples, helping oncologists select the most effective treatment plans for individual patients. This approval was facilitated by the FDA's commitment to advancing personalized medicine through flexible regulatory pathways, recognizing the potential of AI to improve treatment outcomes in cancer care.

Case Study 2: AI in Drug Discovery
The 21st Century Cures Act has played a significant role in promoting the use of AI in drug discovery, particularly for personalized medicine. By streamlining the drug development process and supporting the use of real-world evidence, the act has enabled pharmaceutical companies to leverage AI algorithms in identifying new drug candidates and predicting their efficacy in specific patient populations. This approach has not only accelerated the drug discovery process but also increased the likelihood of success in clinical trials.

Case Study 3: Wearable Health Technologies
The integration of AI with wearable health technologies offers a compelling example of personalized medicine in preventive care. Federal support for digital health initiatives, including regulatory guidance for wearable devices that monitor health indicators, has paved the way for the development and adoption of AI-powered wearables. These devices provide personalized health insights and early warnings based on real-time data, empowering patients to take proactive steps in managing their health.

5. Advancing Patient-Centric Care through Policy and AI
In the pursuit of a more patient-centric healthcare system, the fusion of AI-driven personalized medicine with supportive federal policies presents an unparalleled opportunity to reshape patient care. This synergy promises to enhance treatment efficacy, improve patient outcomes, and streamline healthcare processes. To fully realize this potential, strategic approaches are needed to leverage federal policies effectively, ensuring they nurture innovation while safeguarding patient data, privacy, and ethical standards. This analysis explores strategies for utilizing federal policies to advance AI-driven personalized medicine, addresses the critical role of patient data and the associated privacy and ethical considerations, and underscores the transformative power of AI in delivering predictive analytics, personalized treatment plans, and real-time patient monitoring.

5.1 Strategies for Leveraging Federal Policies
5.1.1 Incentivizing Innovation in AI and Personalized Medicine
Federal policies can stimulate innovation by offering incentives for research and development in AI-driven personalized medicine. These incentives can take various forms, including tax credits, grants, and expedited regulatory pathways for AI-based therapeutic tools and diagnostics. By recognizing and financially supporting the unique challenges of developing and implementing AI in healthcare, these policies can lower barriers to entry and encourage both startups and established companies to invest in personalized medicine solutions.

5.1.2 Establishing Collaborative Public-Private Partnerships
Forging partnerships between government agencies, academic institutions, healthcare providers, and private sector entities can accelerate the development and adoption of AI-driven personalized medicine. These partnerships can leverage diverse expertise and resources, facilitating large-scale research projects, data sharing initiatives, and the development of standards for AI in healthcare. Federal policies that promote such collaborations can help overcome silos in healthcare research and development, fostering a more integrated approach to patient-centric care.

5.1.3 Creating a Flexible Regulatory Framework
A flexible regulatory framework that adapts to the rapid pace of AI innovation is essential for advancing personalized medicine. This framework should balance the need for rigorous evaluation of AI tools to ensure safety and efficacy with the need to avoid undue delays in bringing beneficial innovations to market. Policies should encourage ongoing dialogue

between regulators, developers, and healthcare practitioners to continuously refine regulatory approaches in response to technological advancements and emerging challenges.

5.2 The Role of Patient Data and Privacy Concerns

The foundation of AI-driven personalized medicine is the vast amount of patient data, ranging from electronic health records (EHRs) to genomic data, lifestyle information, and real-time monitoring data. The effective use of this data is contingent upon robust privacy protections and ethical considerations.

5.2.1 Strengthening Data Privacy Protections

Federal policies must ensure strong data privacy protections to maintain patient trust in AI-driven healthcare solutions. This includes enforcing stringent standards for data anonymization, secure data storage, and controlled access. Policies such as updates to the Health Insurance Portability and Accountability Act (HIPAA) can be tailored to address the nuances of AI and big data, providing clear guidelines for the ethical use of patient data in research and clinical care.

5.2.2 Addressing Ethical Considerations

Ethical considerations in AI-driven personalized medicine encompass fairness, transparency, and accountability. Policies should promote ethical AI development, ensuring that algorithms are free from biases that could lead to unequal treatment outcomes among different patient populations. Furthermore, patients should have clear information about how their data is used, the benefits and risks of AI-driven treatments, and the mechanisms in place to safeguard their rights and privacy.

5.3 Transformative Potential of AI in Patient Care

AI-driven personalized medicine has the transformative potential to reshape patient care through predictive analytics, personalized treatment plans, and real-time monitoring.

5.3.1 Enhancing Predictive Analytics

AI can analyze complex datasets to identify patterns and predict health outcomes, enabling earlier interventions for diseases and tailored prevention strategies. Federal support for research into predictive analytics can lead to breakthroughs in identifying risk factors for chronic diseases, predicting disease progression, and optimizing preventive healthcare measures.

5.3.2 Facilitating Personalized Treatment Plans

AI-driven tools can integrate data from various sources, including genomics and EHRs, to develop personalized treatment plans. These plans can be tailored to the genetic makeup, lifestyle, and preferences of individual patients, improving treatment efficacy and patient satisfaction. Policies that encourage the integration of these tools into clinical practice can make personalized treatment plans a standard aspect of patient care.

5.3.3 Real-Time Monitoring and Intervention

Wearable devices and mobile health applications powered by AI can provide real-time monitoring of patients' health indicators. This continuous data stream enables proactive management of chronic conditions, early detection of potential health issues, and timely interventions. Federal policies that support the adoption of these technologies can enhance patient engagement in their care, improve health outcomes, and reduce healthcare costs.

6. Conclusion:

As we stand on the brink of a healthcare revolution, the synergy between AI-driven personalized medicine and evolving federal policies is poised to redefine patient care. The discussions and analyses presented underscore the transformative potential of integrating artificial intelligence with individualized treatment strategies, emphasizing the critical role of supportive federal policies in nurturing this integration. This conclusion seeks to encapsulate the essence of our findings, reflect on the promising horizon of AI-driven personalized medicine, and offer actionable recommendations for stakeholders aiming to foster an ecosystem conducive to innovation in patient-centric care.

6.1 Summarizing Key Findings and Discussions

The journey through the landscape of AI-driven personalized medicine and federal policies reveals a dynamic interplay between technological innovation and regulatory frameworks. We've seen how federal initiatives and regulations, from the Precision Medicine Initiative to the 21st Century Cures Act, have laid a foundational support for the advancement of personalized medicine. The critical importance of patient data, coupled with the paramount concerns of privacy and ethics, has been highlighted, illustrating the complex balance between leveraging data for innovation and ensuring robust protections for individuals.

The discussions have illuminated the challenges and opportunities inherent in harmonizing technological advancements with regulatory requirements. Through case studies and examples, we've observed the tangible impacts of federal policies on the development and deployment of AI-driven solutions, showcasing the potential for significant advancements in patient care when innovation is thoughtfully supported by policy.

6.2 Reflecting on the Future

Looking ahead, the future of AI-driven personalized medicine is bright, with boundless possibilities for enhancing patient outcomes, streamlining healthcare delivery, and personalizing treatment to unprecedented levels. However, this future is contingent upon the evolution of federal policies that not only keep pace with technological advancements but also proactively foster an environment where innovation can flourish. As AI technologies continue to advance, their integration into healthcare will undoubtedly face new challenges, but also open up new opportunities for improving patient care.

The ongoing dialogue between policymakers, healthcare providers, and AI developers will be instrumental in shaping a healthcare ecosystem that embraces the potential of AI-driven personalized medicine. This collaboration is essential for addressing emerging ethical considerations, data privacy concerns, and the need for equitable access to the benefits of personalized medicine.

6.3 Recommendations for Stakeholders

For **policymakers**, the path forward involves crafting policies that are as nimble and innovative as the technologies they aim to regulate. It is crucial to establish a regulatory environment that encourages innovation while ensuring patient safety and ethical integrity. Policymakers should continue to engage with technological experts, healthcare providers, and patients to understand the practical implications of AI in medicine and adjust regulatory frameworks accordingly.

Healthcare providers are encouraged to embrace the advent of AI-driven personalized medicine by staying abreast of technological advancements and integrating AI tools into clinical practice judiciously. Providers should advocate for and participate in continuous education on AI technologies and personalized medicine approaches, ensuring they can effectively leverage these tools to enhance patient care.

For **AI developers**, the recommendation is to prioritize transparency, ethics, and patient privacy in the development of AI-driven healthcare solutions. Engaging with regulatory bodies, healthcare professionals, and patients can provide invaluable insights into the practical needs and ethical considerations of integrating AI into patient care. Developers should also focus on creating solutions that are accessible and equitable, ensuring the benefits of AI-driven personalized medicine can be realized by all segments of the population.

6.4 Fostering a Conducive Environment for Innovation

The collective efforts of policymakers, healthcare providers, and AI developers are pivotal in creating a conducive environment for innovation in patient-centric care. By prioritizing collaboration, ethical considerations, and regulatory agility, stakeholders can ensure that AI-driven personalized medicine continues to advance in a manner that benefits patients and society at large.

The horizon of AI-driven personalized medicine is expansive, offering a vision of healthcare that is more effective, efficient, and tailored to the individual needs of patients. As we navigate this promising future, the concerted actions of all stakeholders will determine the extent to which this vision becomes a reality. In embracing the challenges and opportunities that lie ahead, we can collectively steer the course of healthcare towards a future where patient-centric care, powered by AI, becomes the standard, transforming the lives of individuals and communities across the globe.

7. References

1. Wiljer, D., & Hakim, Z. (2019). Developing an artificial intelligence–enabled health care practice: rewiring health care professions for better care. Journal of medical imaging and radiation sciences, 50(4), S8-S14.
2. Kelly, C. J., Karthikesalingam, A., Suleyman, M., Corrado, G., & King, D. (2019). Key challenges for delivering clinical impact with artificial intelligence. BMC medicine, 17, 1-9.
3. Lin, H. S., & Stead, W. W. (Eds.). (2009). Computational technology for effective health care: immediate steps and strategic directions.
4. Luckin, R., & Holmes, W. (2016). Intelligence unleashed: An argument for AI in education.
5. van Gemert-Pijnen, J. E., Nijland, N., van Limburg, M., Ossebaard, H. C., Kelders, S. M., Eysenbach, G., & Seydel, E. R. (2011). A holistic framework to improve the uptake and impact of eHealth technologies. Journal of medical Internet research, 13(4), e1672.
6. Reddy, S., Fox, J., & Purohit, M. P. (2019). Artificial intelligence-enabled healthcare delivery. Journal of the Royal Society of Medicine, 112(1), 22-28.
7. Holmes, J., Sacchi, L., & Bellazzi, R. (2004). Artificial intelligence in medicine. Ann R Coll Surg Engl, 86, 334-8.
8. Gilvary, C., Madhukar, N., Elkhader, J., & Elemento, O. (2019). The missing pieces of artificial intelligence in medicine. Trends in pharmacological sciences, 40(8), 555-564.
9. Shortliffe, E. H. (2019). Artificial intelligence in medicine: weighing the accomplishments, hype, and promise. Yearbook of medical informatics, 28(01), 257-262.
10. Van Hartskamp, M., Consoli, S., Verhaegh, W., Petkovic, M., & Van de Stolpe, A. (2019). Artificial intelligence in clinical health care applications. Interactive journal of medical research, 8(2), e12100.
11. Becker, A. (2019). Artificial intelligence in medicine: What is it doing for us today?. Health Policy and Technology, 8(2), 198-205.
12. Magrabi, F., Ammenwerth, E., McNair, J. B., De Keizer, N. F., Hyppönen, H., Nykänen, P., ... & Georgiou, A. (2019). Artificial intelligence in clinical decision support: challenges for evaluating AI and practical implications. Yearbook of medical informatics, 28(01), 128-134.